Revance Therapeutics, Inc. Provides RHA® Collection Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021
For the full year, the company expects unaudited RHA® Collection revenue of between $70.0 million and $71.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.87 USD | +2.50% |
|
-3.37% | -67.35% |
1st Jan change | Capi. | |
---|---|---|
-67.35% | 300M | |
+2.22% | 93.53B | |
-1.71% | 38.27B | |
-12.83% | 32.84B | |
-12.14% | 16.08B | |
-0.68% | 14.02B | |
-12.63% | 11.47B | |
+163.45% | 9.92B | |
-53.23% | 9.42B | |
+3.52% | 8.98B |